ASH 2001: abstract 3511
Combination STI-571 + Ara-C is safe
MTD: Imatinib 400 mg QD & ara-c 20 mg/m2 days 15-28.
____________________________________________________________ CHRONIC PHASE ------------------------------------------------------------ INTERFERON r alpha 2bIFN at 5 x 10(6)IU/m2 subcutaneously QD N Engl J Med 330(2):820, 1994 J Natl Cancer Inst; 89(21):1616-20 1997 Blood; 82(10):2975-84 1993 Ann Intern Med; 122(4):254-61 1995 Blood; 92(5):1541-8 1998 ------------------------------------------------------------ INTERFERON + CYTARABIN INTERFERON alfa-2b 5 million units per square meter of body-surface area per day CYTARABINE 20 mg/m2 per day X 10 days Q month 3-year survival rate was 85.7% with interferon+cytarabine & 79.1% with interferon alone. The rate of hematologic response was higher in the interferon-cytarabine group than in the interferon group (P = 0.003). Major cytogenetic responses were observed 12 months after randomization in 126 of 311 patients treated with interferon+cytarabine (41%) & in 75 of 314 patients treated with interferon only (24%, P<0.001). Ref:Guilhot F, et al. New England Journal of Medicine 337(4): 223-229, 1997. ------------------------------------------------------------ HYDROXYUREA Hydroxyurea 1-3 grams /day as a single dose on an empty stomach. Hydroxyurea is superior to busulfan in the chronic phase of CML, with significantly longer median survival & significantly fewer severe adverse effects. The median survival of the busulfan treated Philadelphia-positive patients is 45.4 months and of the hydroxyurea group 58.2 months (P = .008). Ref: Hehlmann R et al. Blood; 82(2):398-407 1993 ------------------------------------------------------------ BUSULFAN Busulfan (Myleran), ---rarely used---, is given PO, either daily 4-8 milligrams per day or in 2-week courses. A dose of 0.1 milligrams/kg/day is often used initially. The dose is halved as the WBC count drops by one half and is discontinued when the WBC count drops below 20,000. ------------------------------------------------------------ Splenectomy may be required and useful in patients having hematologic problems and physical discomfort from a massive spleen. ------------------------------------------------------------ ____________________________________________________________ ACCELERATED PHASE ------------------------------------------------------------ Daunorubicin 120 mg/m2 IV on DAY 1, Cytarabine (ara-C) 1.5 g/m2/d CI over 24 hours for 4 days, Solu-Medrol (methylprednisolone) 100 mg/d for 5 days, Followed on day 5 by GM-CSF 125 micrograms/m2/d over 6 hours until recovery of granulocyte count above 2.0 x 10(3)/microliters Kantarjian HM, et al. J Clin Oncol; 10(3):398-405 1992 ------------------------------------------------------------ ____________________________________________________________ BLAST PHASE ------------------------------------------------------------ Daunorubicin 120 mg/m2 IV on DAY 1, Cytarabine (ara-C) 1.5 g/m2/d CI over 24 hours for 4 days, Solu-Medrol (methylprednisolone) 100 mg/d for 5 days, Followed on day 5 by GM-CSF 125 micrograms/m2/d over 6 hours until recovery of granulocyte count above 2.0 x 10(3)/microliters Kantarjian HM, et al. J Clin Oncol; 10(3):398-405 1992 ------------------------------------------------------------ MITOXANTRONE + HIGH-DOSE ARAC Mitoxantrone 5 mg/m2 intravenously daily for 5 days, Cytosine arabinoside 3 g/m2 IV over 2 hours every 12 hours for six doses 26% achieved complete remission, and one 4% had a partial remission for an overall response rate of 30%. The median survival was 14 weeks for the total population, and 24 weeks for patients achieving a complete remission. Kantarjian HM et al. Cancer; 62(4):672-6 1988 ------------------------------------------------------------ MITOXANTRONE + AZACYTIDINE mitoxantrone, 12 mg/m2 per day for three days and 5-azacytidine 150 mg/m2 per day for 5 days overall response rate:23%, including five complete responders, two partial responders, & two with hematologic improvement. Dutcher JP, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia; 6(8):770-5 1992 ------------------------------------------------------------ *** For Philadelphia-Chromosome-positive (Ph-positive) acute lymphocytic leukemia (ALL) blast phase: Vincristine 0.4 mg CIV X 4 days; Doxorubicin 12 mg/m2 CIV X 4 days; Decadron 40 mg QD on DAYS 1-4, 9-12, & 17-20 (VAD). Course 2 was given starting on day 24 with the addition of cyclophosphamide 1 g/m2. 9 patients achieved CR (30%) and 3 attained a PR (10%), for an overall RR of 40% Walters RS et al. Cancer; 60(8):1708-12 1987 ------------------------------------------------------------
|